Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 03/09/2021

Summary

Translate Bio, Inc. [TBIO] director Ronald C. Renaud, Jr., whose officer title is printed as Chief Executive Officer, reports a stock option grant on 03/09/2021 in this Form 4. The grant gives a right to buy 325,000 shares of common stock at $23.82, expiring 03/09/2031, and the reporting person owns the 325,000 options directly afterward. The footnote sets the vesting at 25% of the shares on March 9, 2022 and thirty-six equal monthly installments for the remainder through March 9, 2025. It is signed /s/ Paul D. Burgess, as attorney-in-fact, on 03/09/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Renaud Ronald C JR (Last) (First) (Middle) C/O TRANSLATE BIO, INC. 29 HARTWELL AVE (Street) LEXINGTON MA 02421 (City) (State) (Zip) | Renaud Ronald C JR | (Last) | (First) | (Middle) | C/O TRANSLATE BIO, INC. | 29 HARTWELL AVE | LEXINGTON | MA | 02421 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Translate Bio, Inc. [ TBIO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer, Pres. | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Executive Officer, Pres.
3. Date of Earliest Transaction
 (Month/Day/Year) 03/09/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (right to buy) | $ 23.82 | 03/09/2021 | A | 325,000 | (1) | 03/09/2031 | Common Stock | 325,000 | $ 0.00 | 325,000 | D
Explanation of Responses:
1. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025.
Remarks:
/s/ Paul D. Burgess, as attorney-in-fact for Ronald C. Renaud, Jr. | 03/09/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_TBIO_4_filed2021-03-09_0001209191-21-019305.xml

Size

15,594 bytes

SHA-256

3e9351148c17070803ebf08b1d8fd43b8921fa8aafbb5d40ec21da3c3ce44b06

Our copy

SEC_TBIO_4_filed2021-03-09_0001209191-21-019305.xml

Original

www.sec.gov